Bausch Health Announces 2025 Annual Meeting of Shareholder Results

Rhea-AI Summary

Bausch Health Companies (NYSE/TSX: BHC) held its 2025 Annual Meeting of Shareholders on May 13, 2025, where shareholders elected all 10 nominated directors to the board. The meeting saw significant participation with vote counts ranging from approximately 199-208 million votes in favor for different directors. Notable directors elected include Thomas J. Appio, Brett M. Icahn, and John A. Paulson.

Additionally, shareholders approved three key items: a non-binding advisory vote on executive compensation, the 2025 Employee Stock Purchase Plan (ESPP), and the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm through the 2026 annual meeting.

["-"]

LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below:

Name		For		Withheld		Broker Non-Votes
Thomas J. Appio		208,400,572		5,943,436		56,339,806
Christian A. Garcia		207,181,762		7,162,246		56,339,806
Brett M. Icahn		199,179,508		15,164,500		56,339,806
Sarah B. Kavanagh		208,164,244		6,179,764		56,339,806
Frank D. Lee		207,489,891		6,854,117		56,339,806
Steven D. Miller		206,805,726		7,538,282		56,339,806
Richard C. Mulligan, Ph.D.		202,866,703		11,477,305		56,339,806
John A. Paulson		205,916,286		8,427,722		56,339,806
Robert N. Power		202,283,418		12,060,590		56,339,806
Amy B. Wechsler, M.D.		207,392,798		6,951,210		56,339,806

At the Annual Meeting, shareholders also approved the non-binding advisory vote on the compensation of the Company's named executive officers, approved the Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan ("ESPP"), and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2026 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange ("TSX") approval with respect to the ESPP, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR profile and on the Company's website at www.bauschhealth.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll free)

Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692

SOURCE: Bausch Health Companies Inc

View the original press release on ACCESS Newswire

FAQ

Who are the directors elected to Bausch Health's board in the 2025 annual meeting?

Ten directors were elected: Thomas J. Appio, Christian A. Garcia, Brett M. Icahn, Sarah B. Kavanagh, Frank D. Lee, Steven D. Miller, Richard C. Mulligan, John A. Paulson, Robert N. Power, and Amy B. Wechsler.

What was the voting outcome for BHC's 2025 Employee Stock Purchase Plan?

The 2025 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the annual meeting.

Who will serve as Bausch Health's independent auditor for 2025-2026?

PricewaterhouseCoopers LLP was appointed as the company's independent registered public accounting firm until the 2026 annual meeting.

Which director received the highest number of 'For' votes at BHC's 2025 annual meeting?

Thomas J. Appio received the highest number of 'For' votes with 208,400,572 votes.